Q4 2019 Cytokinetics Inc Earnings Call Transcript
Good afternoon and welcome, ladies and gentlemen, to Cytokinetics' Fourth Quarter 2019 Conference Call. At this time, I'd like to inform you that this call is being recorded. (Operator Instructions)
I'll now turn the call over to Diane Weiser, Cytokinetics' Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with key 2019 accomplishments and a review of our Vision 2025. Then Fady Malik, our EVP of Research and Development, will provide updates on key developments for omecamtiv mecarbil, our cardiac myosin activator, and AMG 594, our cardiac troponin activator, both under our collaboration with Amgen. Next, Fady will update on recent progress with CK-274, our wholly owned cardiac myosin inhibitor now in Phase II; and CK-271, our additional cardiac myosin inhibitor. Andy Wolff, our Chief Medical Officer
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |